<DOC>
	<DOCNO>NCT01048905</DOCNO>
	<brief_summary>The primary hypothesis study glutamine supplementation improve erythrocyte glutamine/glutamate ratio , biomarker oxidative stress , hemolysis pulmonary hypertension ( PH ) sickle cell disease ( SCD ) thalassemia ( Thal ) patient PH . PH define tricuspid regurgitant jet velocity ( TRV ) Doppler echocardiography &gt; 2.5 m/s . We also predict glutamine therapy increase arginine bioavailability subsequently alter sickle red cell endothelial interaction identify use endo-PAT technology nitric oxide ( NO ) generation , leading change biological marker , clinical outcome . Specifically second hypothesis oral glutamine decrease biomarkers hemolysis adhesion molecule , improve imbalanced arginine-to-ornithine ratio occur hemolytic anemia , lead improve arginine bioavailability clinical endpoint endothelial dysfunction PH patient SCD Thal .</brief_summary>
	<brief_title>Glutamine Therapy Hemolysis-Associated Pulmonary Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<criteria>Established diagnosis SCD ( Hb SS , SC SBeta thalassemia ) Thal PH document echocardiography , define TRV great 2.5 m/s Age great equal 4 year Inability take tolerate oral medication Acute crisis hospitalization within 1 month enrollment Hepatic dysfunction ( SGPT great 3X normal ) Renal dysfunction ( Creatinine great 2X normal ) Allergy glutamine Pregnancy breastfeeding Patients sildenafil ( Viagra ) , calcium channel blocker , amino acid/protein supplement ( therapy acceptable stable 3 month )</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Pulmonary Hypertension</keyword>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Thalassemia</keyword>
</DOC>